Reduction of exacerbations by the PDE4 inhibitor roflumilast - the importance of defining different subsets of patients with COPD

Respiratory Research

Volumn 12, Issue , 2011, Pages

  Rennard, Stephen I ^a   Calverley, Peter M A ^b   Goehring, Udo M ^c   Bredenbröker, Dirk ^c   Martinez, Fernando J ^d  

^a NEBRASKA MEDICAL CENTER   (United States)

^b UNIVERSITY HOSPITAL AINTREE   (United Kingdom)

^c Nycomed GmbH   (Germany)

^d UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; PHOSPHODIESTERASE IV; ROFLUMILAST; AMINOPYRIDINE DERIVATIVE; ANTIINFLAMMATORY AGENT; BENZAMIDE DERIVATIVE; CYCLOPROPANE DERIVATIVE; PHOSPHODIESTERASE IV INHIBITOR;

ARTICLE; BODY MASS; CHRONIC BRONCHITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CORTICOSTEROID THERAPY; COUGHING; DIARRHEA; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG SAFETY; FORCED EXPIRATORY VOLUME; HEADACHE; HEALTH STATUS; HUMAN; INFLUENZA; LUNG EMPHYSEMA; LUNG FUNCTION; MAJOR CLINICAL STUDY; NAUSEA; PNEUMONIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); RHINOPHARYNGITIS; SIDE EFFECT; SMOKING; SPUTUM; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; WEIGHT REDUCTION; AGED; DOUBLE BLIND PROCEDURE; DRUG ADMINISTRATION; DRUG EFFECT; ENZYMOLOGY; FEMALE; LUNG; MALE; META ANALYSIS; METHODOLOGY; MIDDLE AGED; MULTICENTER STUDY (TOPIC); ORAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; PATIENT SELECTION; PHASE 3 CLINICAL TRIAL (TOPIC); PROPORTIONAL HAZARDS MODEL; RISK ASSESSMENT; RISK FACTOR; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; AGED; AMINOPYRIDINES; ANTI-INFLAMMATORY AGENTS; BENZAMIDES; CLINICAL TRIALS, PHASE III AS TOPIC; CYCLOPROPANES; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; LUNG; MALE; MIDDLE AGED; MULTICENTER STUDIES AS TOPIC; PATIENT SELECTION; PHOSPHODIESTERASE 4 INHIBITORS; PROPORTIONAL HAZARDS MODELS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME;

EID: 79251588730     PISSN: 14659921     EISSN: 1465993X     Source Type: Journal    
DOI: 10.1186/1465-9921-12-18     Document Type: Article

References (24)

1. Chapman KR, Mannino DM, Soriano JB, Vermeire PA, Buist AS, Thun MJ, Connell C, Jemal A, Lee TA, Miravitlles M, Aldington S, Beasley R. Epidemiology and costs of chronic obstructive pulmonary disease. Eur Respir J 2006, 27:188-207. 10.1183/09031936.06.00024505, 16387952.
2. Halbert RJ, Natoli JL, Gano A, Badamgarav E, Buist AS, Mannino DM. Global burden of COPD: systematic review and meta-analysis. Eur Respir J 2006, 28:523-532. 10.1183/09031936.06.00124605, 16611654.
3. Pauwels RA, Rabe KF. Burden and clinical features of chronic obstructive pulmonary disease (COPD). Lancet 2004, 364:613-620. 10.1016/S0140-6736(04)16855-4, 15313363.
4. Spencer S, Calverley PM, Burge PS, Jones PW. Impact of preventing exacerbations on deterioration of health status in COPD. Eur Respir J 2004, 23:698-702. 10.1183/09031936.04.00121404, 15176682.
5. Soler-Cataluna JJ, Martinez-Garcia MA, Roman SP, Salcedo E, Navarro M, Ochando R. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax 2005, 60:925-931. 10.1136/thx.2005.040527, 1747235, 16055622.
6. Gamble E, Grootendorst DC, Brightling CE, Troy S, Qiu Y, Zhu J, Parker D, Matin D, Majumdar S, Vignola AM, Kroegel C, Morell F, Hansel TT, Rennard SI, Compton C, Amit O, Tat T, Edelson J, Pavord ID, Rabe KF, Barnes NC, Jeffery PK. Antiinflammatory effects of the phosphodiesterase-4 inhibitor cilomilast (Ariflo) in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2003, 168:976-982. 10.1164/rccm.200212-1490OC, 12816740.
7. Grootendorst DC, Gauw SA, Verhoosel RM, Sterk PJ, Hospers JJ, Bredenbroker D, Bethke TD, Hiemstra PS, Rabe KF. Reduction in sputum neutrophil and eosinophil numbers by the PDE4 inhibitor roflumilast in patients with COPD. Thorax 2007, 62:1081-1087. 10.1136/thx.2006.075937, 2094292, 17573446.
8. Global Initiative for Chronic Obstructive Lung Disease Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease (updated 2009). 2009, Bethesda: National Heart, Lung and Blood Institute, Global Initiative for Chronic Obstructive Lung Disease.
9. Rabe KF, Bateman ED, O'Donnell D, Witte S, Bredenbroker D, Bethke TD. Roflumilast - an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2005, 366:563-571. 10.1016/S0140-6736(05)67100-0, 16099292.
10. Calverley PM, Sanchez-Toril F, McIvor A, Teichmann P, Bredenbroeker D, Fabbri LM. Effect of 1-year treatment with roflumilast in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007, 176:154-161. 10.1164/rccm.200610-1563OC, 17463412.
11. Rennard SI, Vestbo J. The many "small COPDs": COPD should be an orphan disease. Chest 2008, 134:623-627. 10.1378/chest.07-3059, 18779197.
12. SPIROMICS (Subpopulations and Intermediate Outcome Measures in COPD Study). , http://www.cscc.unc.edu/spir/
13. Regan EA, Hokanson JE, Murphy JR, Make B, Lynch DA, Beaty TH, Curran-Everett D, Silverman EK, Crapo JD. Genetic epidemiology of COPD (COPDGene) study design 2. COPD 2010, 7:32-43. 10.3109/15412550903499522, 20214461.
14. Vestbo J, Anderson W, Coxson HO, Crim C, Dawber F, Edwards L, Hagan G, Knobil K, Lomas DA, MacNee W, Silverman EK, Tal-Singer R. Evaluation of COPD Longitudinally to Identify Predictive Surrogate End-points (ECLIPSE). Eur Respir J 2008, 31:869-873. 10.1183/09031936.00111707, 18216052.
15. Calverley PM, Rabe KF, Goehring UM, Kristiansen S, Fabbri LM, Martinez FJ. Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet 2009, 374:685-694. 10.1016/S0140-6736(09)61255-1, 19716960.
16. Soto FJ, Hanania NA. Selective phosphodiesterase-4 inhibitors in chronic obstructive lung disease. Curr Opin Pulm Med 2005, 11:129-134.
17. Calverley P, Pauwels R, Vestbo J, Jones P, Pride N, Gulsvik A, Anderson J, Maden C. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2003, 361:449-456. 10.1016/S0140-6736(03)12459-2, 12583942.
18. Calverley PM, Boonsawat W, Cseke Z, Zhong N, Peterson S, Olsson H. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur Respir J 2003, 22:912-919. 10.1183/09031936.03.00027003, 14680078.
19. Ito K, Ito M, Elliott WM, Cosio B, Caramori G, Kon OM, Barczyk A, Hayashi S, Adcock IM, Hogg JC, Barnes PJ. Decreased histone deacetylase activity in chronic obstructive pulmonary disease. N Engl J Med 2005, 352:1967-1976. 10.1056/NEJMoa041892, 15888697.
20. Seemungal TA, Donaldson GC, Paul EA, Bestall JC, Jeffries DJ, Wedzicha JA. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998, 157:1418-1422.
21. Guerra S, Sherrill DL, Venker C, Ceccato CM, Halonen M, Martinez FD. Chronic bronchitis before age 50 years predicts incident airflow limitation and mortality risk. Thorax 2009, 64:894-900. 10.1136/thx.2008.110619, 19581277.
22. Hebenstreit GF, Fellerer K, Fichte K, Fischer G, Geyer N, Meya U, Hernandez M, Schony W, Schratzer M, Soukop W. Rolipram in major depressive disorder: results of a double-blind comparative study with imipramine. Pharmacopsychiatry 1989, 22:156-160. 10.1055/s-2007-1014599, 2668980.
23. Han MK, Agusti A, Calverley PM, Celli BR, Criner G, Curtis JL, Fabbri LM, Goldin JG, Jones PW, MacNee W, Make BJ, Rabe KF, Rennard SI, Sciurba FC, Silverman EK, Vestbo J, Washko GR, Wouters EF, Martinez FJ. Chronic obstructive pulmonary disease phenotypes: the future of COPD. Am J Respir Crit Care Med 2010, 182:598-604. 10.1164/rccm.200912-1843CC, 20522794.
24. Calverley PM. COPD: what is the unmet need?. Br J Pharmacol 2008, 155:487-493. 10.1038/bjp.2008.362, 2579674, 18794891.